Animal NDC 58198-8602-5 Milbemite

Milbemycin Oxime

Animal Product Information

Field Name Field Value
Animal NDC Code 58198-8602-5
Proprietary Name Milbemite What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
Non-Proprietary Name Milbemycin Oxime What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
Labeler Name Elanco Us Inc.
Product Type Prescription Animal Drug
Usage Information
    MILBEMITE OTIC Solution is indicated for treatment of ear mite (Otodectes cynotis) infestations in cats and kittens four weeks of age and older. Effectiveness is maintained throughout the life cycle of the ear mite.
Active Ingredient(s)
  • Milbemycin Oxime
Marketing Category NADA - NEW ANIMAL DRUG APPLICATION What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
FDA Application Number NADA141163 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Milbemite Animal Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Table of Contents



Other



(0.1% milbemycin oxime)

Caution: U.S. Federal law restricts this drug to use by or on the order of a licensed veterinarian.


Description:



MILBEMITE OTIC Solution is available in plastic dispensing tubes. Each plastic tube contains 0.25 mL of MILBEMITE OTIC Solution as a 0.1% solution of milbemycin oxime. Milbemycin oxime consists of the oxime derivatives of 5-didehydromilbemycins in the ratio of approximately 80% A4 (C32H45NO7, MW 555.71) and 20% A3 (C31H43NO7, MW 541.68).


Indications:



MILBEMITE OTIC Solution is indicated for treatment of ear mite (Otodectes cynotis) infestations in cats and kittens four weeks of age and older. Effectiveness is maintained throughout the life cycle of the ear mite.


Human Warnings:



Not for human use. Keep this and all drugs out of the reach of children.


Precautions:



The safe use of MILBEMITE OTIC Solution in cats used for breeding purposes, during pregnancy, or in lactating queens, has not been evaluated.


Adverse Reactions:



No adverse reactions caused by MILBEMITE OTIC Solution have been reported in controlled effectiveness studies in adult cats and kittens (4 weeks of age).


Dosage:



MILBEMITE OTIC Solution should be administered topically into the external ear canal as the entire contents of a single-dose tube per ear. The volume delivered will be approximately 0.2 mL, with 0.05 mL residual volume remaining in dispensing tube. Repeat the treatment one time if necessary, based upon the ear mite life cycle and the response to treatment.


Administration:



MILBEMITE OTIC Solution should be administered as one tube per ear as a single treatment. Each foil pouch contains two tubes of solution, one for each ear. Open the tube by pressing cap down firmly to break seal. Remove cap and check to be sure tip of tube is open. Squeeze the tube to administer the contents of one tube into each external ear canal. Massage the base of the ear for optimal distribution. In clinical field trials, ears were not cleaned and many animals still had debris in their ears at the end of the study. Cleaning of the external ear canal prior to treatment may be performed, but is not necessary to provide effectiveness.


Effectiveness:



The clinical effectiveness of milbemycin oxime 0.1% solution was evaluated in a placebo-controlled clinical field trial of client-owned cats. Otodectes cynotis infestation was diagnosed by direct microscopic visualization of ear swab debris. Test or placebo treatment was administered to both ears of the cat following the pre-treatment examination. Cats’ ears were examined by ear swab microscopy at multiple intervals throughout the life cycle of the mite (up to day 30). Ninety-nine percent (99%) of the milbemycin oxime-treated group were ear mite negative at the microscopic exams.


Safety:



A study was conducted using otic doses of 0.1, 0.3 or 0.5% milbemycin oxime solutions administered once weekly for six applications in kittens that were 4 weeks of age at the initiation of the study. Otic doses of 0.1 and 0.3% did not produce adverse systemic or local effects. One kitten treated with 0.5% was lethargic 8 hours after the second treatment. The kitten was offered milk replacer and by 10 hours post-treatment it appeared normal. In this kitten, lethargy was not observed after subsequent treatments. A study was conducted to evaluate the safety of a 0.1% milbemycin oxime solution in adult cats. Topical doses at 1X, 3X or 5X the recommended dose applied in one ear did not produce adverse effects.


Storage Conditions:



MILBEMITE OTIC Solution should be stored at room temperature, between 59° and 77°F (15-25°C).


How Supplied:



MILBEMITE OTIC Solution is supplied in individual white polypropylene tubes, paired in a foil overlay pouch. The product is packaged in a box of 10 pouches of 2 tubes of 0.25 mL each.

Product of Japan

Manufactured for: Elanco US Inc.
                           Greenfield, IN 46140, USA

Approved by FDA under NADA # 141-163

Milbemite, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.

© 2022 Elanco or its affiliates

Revision Date: May 2022

PA103718X

ElancoTM


Principal Display Panel - Carton Label



MilbeMite™

OTIC Solution (0.1% milbemycin oxime)

A topical medication for the treatment of ear mite
(Otodectes cynotis) infestations in cats and kittens.

FOR USE IN CATS & KITTENS
FOUR WEEKS OF AGE AND OLDER

Net Contents:
10 pouches of
2 tubes of
0.25 mL each


Principal Display Panel - Pouch Label



MilbeMite™

OTIC Solution (0.1% milbemycin oxime)

For the treatment of ear mite (Otodectes cynotis)
infestations in cats and kittens.

FOR USE IN CATS & KITTENS FOUR WEEKS OF
AGE AND OLDER

Net Contents: 2 tubes of 0.25 mL each

HUMAN WARNINGS:
Not for human use. Keep this and all drugs out
of the reach of children.

CAUTION: Federal (USA) law restricts this drug
to use by or on the order of a licensed veterinarian.


* The information on this page is for an ANIMAL PRODUCT, please review the complete disclaimer below.